202 related articles for article (PubMed ID: 34167036)
1. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.
Matarazzo MG; Sarpietro G; Fiorito D; Di Pasqua S; Ingrassano S; Panella MM; Cianci A; Caruso S
Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():67-71. PubMed ID: 34167036
[TBL] [Abstract][Full Text] [Related]
2. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy.
Russo E; Misasi G; Montt-Guevara MM; Giannini A; Simoncini T
Climacteric; 2023 Jun; 26(3):284-288. PubMed ID: 36912363
[TBL] [Abstract][Full Text] [Related]
3. A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.
Schiavi MC; Di Tucci C; Colagiovanni V; Faiano P; Giannini A; D'Oria O; Prata G; Perniola G; Monti M; Zullo MA; Muzii L; Benedetti Panici P
Low Urin Tract Symptoms; 2019 Apr; 11(2):O11-O15. PubMed ID: 29057583
[TBL] [Abstract][Full Text] [Related]
4. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
5. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Gilbert L; Martel C; Balser J
J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
[TBL] [Abstract][Full Text] [Related]
6. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Holton M; Thorne C; Goldstein AT
Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
[No Abstract] [Full Text] [Related]
7. Does the Time of Onset of Urinary Symptoms Affect Microablative Fractional CO
Ruffolo AF; Casiraghi A; Marotta E; Degliuomini R; Parma M; Athanasiou S; Benini V; Candiani M; Salvatore S
Lasers Surg Med; 2021 Sep; 53(7):953-959. PubMed ID: 33476052
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
10. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?
Schiavi MC; Sciuga V; Giannini A; Vena F; D'oria O; Prata G; Di Tucci C; Savone D; Aleksa N; Capone C; Di Mascio D; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2018 Aug; 34(8):666-669. PubMed ID: 29463148
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
12. Ultralow 0.03 mg vaginal estriol in postmenopausal women who underwent surgical treatment for stress urinary incontinence: effects on quality of life and sexual function.
Caruso S; Cianci A; Sarpietro G; Matarazzo MG; Panella M; Cianci S
Menopause; 2020 Feb; 27(2):162-169. PubMed ID: 31834156
[TBL] [Abstract][Full Text] [Related]
13. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms.
Schiavi MC; Zullo MA; Faiano P; D'Oria O; Prata G; Colagiovanni V; Giannini A; Di Tucci C; Perniola G; Di Donato V; Monti M; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2017 Dec; 33(12):942-945. PubMed ID: 28490209
[TBL] [Abstract][Full Text] [Related]
15. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
[TBL] [Abstract][Full Text] [Related]
16. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
[TBL] [Abstract][Full Text] [Related]
17. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results.
Perino A; Cucinella G; Gugliotta G; Saitta S; Polito S; Adile B; Marci R; Calagna G
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2491-7. PubMed ID: 27383297
[TBL] [Abstract][Full Text] [Related]
18. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Archer DF; Labrie F; Bouchard C; Portman DJ; Koltun W; Cusan L; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
[TBL] [Abstract][Full Text] [Related]
20. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
Cipriani S; Maseroli E; Ravelli SA; Vignozzi L
Climacteric; 2023 Aug; 26(4):309-315. PubMed ID: 37288964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
